Please login to the form below

Not currently logged in


This page shows the latest ABT-450 news and features for those working in and with pharma, biotech and healthcare.

AbbVie closes in on US approval of all-oral hepatitis C regimen

FDA grants priority review to company’ s protease inhibitor ABT-450 regimen. ... The regimen consists of the protease inhibitor ABT-450 boosted by ritonavir and co-formulated with the polymerase inhibitor dasabuvir, alongside NS5A inhibitor ombitasvir,

Latest news

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest from PMHub

  • Warehousing of HCV patients reaches new high

    However, Abbvie’ s products ABT 267, ABT 333 and ABT 450 remain contenders for market share, scoring higher than J&J’ s simeprevir in terms of likelihood to prescribe amongst doctors

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Brandcast Health

Brandcast Health is a digital MedComms and patient-engagement agency who help our clients create and share engaging content. Our innovative...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...